Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 7, 2012, Pages 515-521

  Malayev, Yuliya ^a   Levene, Richard ^b   Gonzalez, Faustino ^c  

^a Nova Southeastern University   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Hospice of Palm Beach County   (United States)

Author keywords

cost concerns; ethics; intraperitoneal chemotherapy; oral palliative agents; ovarian cancer; quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ASCITES; ECONOMICS; FEMALE; HUMAN; INFUSION; METHODOLOGY; OVARY TUMOR; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; ASCITES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 84867706386     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111434044     Document Type: Review

References (71)

1. Schorge JO,Schaffer JI,Halvorson LM, et alWilliams Gynecology. New York, NY: McGraw Hill Medical; 2008:.
2. Jelovac D,Armstrong DK.Recent progress in the diagnosis and treatment of ovarian cancer.A Cancer J Clin. 2011;61 (3): 183-203.
3. Arriba L,Fader A,Frasure H,von Gruenigen V.A review of issues surrounding quality of life among women with ovarian cancer.Gynecol Oncol. 2010;119 (2): 390-396.
4. Vergote I,Trope CG,Amant F, et al.Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N Engl J Med. 2010;363 (10): 943-953.
5. Goff BA,Mandel LS,Melancon CH,Muntz HG.Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.JAMA. 2004;291 (22): 2705-2712.
6. Buys SS,Partridge E,Black A, et al.Effect of screening on ovarian cancer mortality-the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial.JAMA. 2011;305 (22): 2295-2303.
7. Yedema CA,Kenemans P,Wobbes T, et al.Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas [Abstract].Tumour Biol. 1992;13 (1-2): 18-26.
8. McGuire WP,Hoskins WJ,Brady MF, et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N Engl J Med. 1996;334 (1): 1-6.
9. Samaritani R,Corrado G,Vizza E,Sbiroli C.Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.BMC Central. 2007;7:65.
10. Hoskins PJ,Le N.Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.Gynecol Oncol. 2005;97 (3): 862-869.
11. Jemal A,Siegel R,Ward E, et al.Cancer statistics.CA Cancer J Clin. 2009;59 (4): 225-249.
12. Harrington SE,Smith TJ.The role of chemotherapy at the end of life: "When is enough, enough?".JAMA. 2008;299 (22): 2667-2678.
13. Alberts DS,Liu PY,Hannigan EV, et al.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.N Engl J Med. 1996;335 (26): 1950-1955.
14. Armstrong DK,Bundy B,Wenzel L, et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med. 2006;354 (1): 34-43.
15. Havrilesky LJ,Secord AA,Darcy KM,Kulasingam S.Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a gynecologic oncology group study.J Clin Oncol. 2008;26 (25): 4144-4150.
16. Patten SG,Adamcic U,Lacombe K,Minhas K,Skowronski K,Coomber BL.VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.BMC Cancer. 2010;10:683-693.
17. Dedrick RL,Myers CE,Bungay PM,DeVita VT JR.Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer [abstract].Cancer Treat Rep. 1978;62 (1): 1-11.
18. Chaudhary K,Haddadin SM,Nistala R,Papageorgio C.Intraperitoneal drug therapy: an advantage [abstract].Current Clin Pharmacol. 2010;5 (2): 82-88.
19. Rosenberg SM.Palliation of malignant ascites.Gastroenterol Clin North Am. 2006;35 (1): 189xi-199xi.
20. Mishra K.Gynaecological malignancies from palliative care perspective.Indian J Palliat Care. 2011;17 (suppl): S45-S51.
21. Baron TH.Expandable Metal stents for the treatment of cancerous obstruction of the gastrointestinal tract.N Engl J Med. 2001;344 (22): 1681-1687.
22. National Cancer Institute.
23. Cella DF,Tulsky DS,Gray G, et al.The functional assessment of cancer therapy scale: development and validation of the general measure [abstract].J Clin Oncol. 1993;11 (3): 570-579.
24. von Gruenigen VE,Hutchins JR,Reidy AM, et al.Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy.Health and Quality of Life Outcomes. 2006;4:84.
25. Penson RT,Dignan F,Seiden MV, et al.Attitudes to chemotherapy in patients with ovarian cancer.Gynecol Oncol. 2004;94 (2): 427-435.
26. Barbera L,Elit L,Krzyzanowska M, et al.End of life care for women with gynecologic cancers.Gynecol Oncol. 2010;118 (2): 196-201.
27. Doyle C,Crump M,Pintilie M,Oza A.Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.J Clin Oncol. 2001;19 (5): 1266-1274.
28. Von Gruenigen VE,Daly BJ.Futility: clinical decisions at the end of life in women with ovarian cancer.Gynecol Oncol. 2005;97 (2): 638-644.
29. Wan GJ,Counte MA,Cella DF.The influence of personal expectations on cancer patients' reports of health related quality of life.Psycho-oncology. 1997;6 (1): 1-11.
30. Slevin ML,Stubbe L,Plant HJ, et al.Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public.BMJ. 1990;300 (6737): 1458-1460.
31. Donovan KA,Greene PG,Shuster JL,Partridge EE,Tucker DC.Treatment preferences in recurrent ovarian cancer.Gynecol Oncol. 2002;86 (2): 200-211.
32. Von Gunten CF.Secondary and tertiary palliative care in US hospitals.JAMA. 2002;287 (7): 875-881.
33. McCartney CF,Larson DB.Quality of life in patients with gynecologic cancer.Cancer. 1987;60 (8 suppl): 2129-2136.
34. Levy MH,Back AM,Benedetti C, et al.NCCN clinical practice guidelines in oncology: palliative care [abstract].J Natl Compr Cancer Netw. 2009;7 (4): 436-473.
35. Keyser EA,Reed B,Lowery W, et al.Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions.Gynecol Oncol. 2010;118 (3): 274-277.
36. Doyle C,Stockler M,Pintilie M, et al.Resource implications of palliative chemotherapy for ovarian cancer [abstract].J Clin Oncol. 1997;15 (3): 1000-1007.
37. Lewin SN,Buttin BM,Powell MA, et al.Resource utilization for ovarian cancer patients at the end of life: how much is too much?.Gynecol Oncol. 2005;99 (2): 261-266.
38. Sistigu A,Vilaud S,Chaput N, et al.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design [Abstract].Seminars in Immunopathology. 2011;33 (4): 369-383.
39. Gasparini G.Metronomic scheduling: the future of chemotherapy?.Lancet oncol. 2001;2 (12): 733-740.
40. Watanabe Y,Etoh T,Koike E, et al.Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer.Int J Clin Oncol. 2010;15 (5): 468-471.
41. D'Amato RJ,Loughnan MS,Flynn E,Folkman J.Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci. 1994;91 (9): 4082-4085.
42. Gordinier ME,Dizon DS,Weitzen S, et al.Oral Thalidomide as palliative chemotherapy in women with advanced ovarian cancer.J Palliat Med. 2007;10 (1): 61-66.
43. Chan JK,Manuel MR,Ciaravino G,Cheung MK,Husain A,Teng NN.Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.Gynecol Oncol. 2006;103 (3): 919-923.
44. Buttin BM,Moore MJ.Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.Gynecol Oncol. 2008;111 (3): 546-548.
45. Ikhlaque N,Seshadri V,Kathula S,Baumann MA.Efficacy of prophylactic warfarin for prevention of thalidomide related deep venous thrombosis.Am J Hematol. 2006;81 (6): 420-422.
46. Downs LS,Judson PL,Argenta PA, et al.A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.Cancer. 2008;112 (2): 331-339.
47. Clements M,Jones C,Cumming M,Daoud SS.Antiangiogenic potential of captothenic and topotecan.Cancer Chemother Pharmacol. 1999;44 (5): 411-416.
48. Armstrong DK.Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.Oncologist. 2004;9 (1): 33-42.
49. McGuire WP,Blessing JA,Bookman MA,Lentz SS,Dunton CJ.Topotecan has substantial antitumor activity as first line salvage therapy in platinum sensitive epithelial ovarian carcinoma: a gynecologic oncology group study.J Clin Oncol. 2000;18 (5): 1062-1067.
50. Swisher EM,Mutch DG,Rader JS,Elbendary A,Herzog TJ.Topotecan in platinum-and paclitaxel-resistant ovarian cancer.Gynecol Oncol. 1997;66 (3): 480-486.
51. Mabuchi S,Ohmichi M,Kimura A, et al.Tamoxifen inhibits cell proliferation via mitogen activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptors or the sensitivity to cisplatin.Endocrinology. 2004;145 (3): 1302-1313.
52. Hurteau JA,Brady MF,Darcy KM, et al.Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a gynecologic oncology group study.Gynecol Oncol. 2010;199 (3): 444-450.
53. Hatch KD,Beecham JB,Blessing JA,Creasman WT.Responsiveness of patients with advanced ovarian carcinoma to tamoxifen, a gynecologic oncology group study of second-line therapy in 105 patients.Cancer. 1991;68 (2): 269-271.
54. Markman M,Iseminger KA,Hatch KD,Creasman WT,Barnes W,Dubeshter B.Tamoxifen in platinum refractory ovarian cancer: a gynecologic oncology group ancillary report.Gynecol Oncol. 1996;62 (1): 4-6.
55. Yan TD,Cao CQ,Munkholm-Larsen S.A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.World J Gastrointest Oncol. 2010;2 (2): 109-116.
56. Los G,Mutsaers PH,Lenglet WJ,Baldew GS,McVie JG.Platinum distribution intraperitoneal tumors after intraperitoneal cisplatin treatment [abstract].Cancer Chemother Pharmacol. 1990;25 (6): 389-394.
57. Howell SB,Pfeifle CL,Wung WE, et al.Intraperitoneal cisplatin with systemic thiosulfate protection.Ann Intern Med. 1982;97 (6): 845-851.
58. Le T,Latifah H,Jolicouer J, et al.Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?.Gynecol Oncol. 2011;121 (3): 451-454.
59. Krasner CN,Roche M,Horowitz NS,Supko JG,Lee SI,Oliva E.Case 11-2006: a 54-year old woman with a mass in the pelvis.N Engl J Med. 2006;354 (15): 1615-1625.
60. Barakat R,Sabbatini P,Bhaskaran D, et al.Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up in 411 patients.J Clin Oncol. 2002;20 (3): 694-698.
61. Wenzel LB,Huang HQ,Armstrong DK, et al.Gynecologic oncology group. Health related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study.J Clin Oncol. 2007;25 (4): 437-443.
62. Markman M.Intraperitoneal antineoplastic drug delivery: rationale and results.Lancet. 2003;4 (5): 277-283.
63. Tanyi JL,McCann G,Hagemann AR, et al.Clinical predictors of bevacizumab-associated gastrointestinal perforation.Gynecol Oncol. 2011;120 (3): 464-469.
64. Eskander RN,Randall LM.Bevacizumab in the treatment of ovarian cancer.Biologics: Targets and Therapy. 2011;5:1-5.
65. Kuh HJ,Jang SH,Wientjes MG, et al.Determinants of paclitaxel penetration and accumulation in human solid tumor.J Pharmacol Exp Ther. 1999;290 (2): 871-880.
66. Young RC,Brady MF,Nieberg RK, et al.Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study.J Clin Oncol. 2003;21 (23): 4350-4355.
67. Gordon AN,Fleagle JT,Guthrie D,Parkin DE,Gore ME,Lacave AJ.Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.J Clin Oncol. 2001;19 (14): 3312-3322.
68. Gordon AN,Granai CO,Rose P, et al.Phase II study of liposomal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer.J Clin Oncol. 2000;18 (17): 3093-3100.
69. Pisano C,Bruni GS,Facchini G, et al.Treatment of recurrent epithelial ovarian cancer.Ther Clin Risk Manag. 2009;5 (4): 421-426.
70. Numnum TM,Rocconi RP,Whitworth J, et al.The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.Gynecol Oncol. 2006;102 (3): 425-428.
71. Hamilton CA,Maxwell GL,Chernofsky MR,Bernstein SA,Farley JH,Rose GS.Intraperitoneal bevacizumab for palliation of malignant ascites in refractory ovarian cancer.Gynecol Oncol. 2008;111 (3): 530-532.